Lithium Ion

Lithium Ion

SCHEMBL4470896

Cc1ccc(-n2nc(C(=O)[O-])cc2-c2ccccn2)cn1.[Li+]

nearest known ligand 0.41

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

GSK3AGSK3BIMPA1

The experimentally established mechanism targets of Lithium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PTGS1 P23219 1/20 0.41
PTGS2 P35354 1/20 0.41
P4HTM Q9NXG6 1/20 0.38
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
RPA1 P27694 4/20 0.36
NPC1 O15118 1/20 0.35
TP53 P04637 1/20 0.35
RAB9A P51151 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
SLC16A3 O15427 1/20 0.35
SLC16A1 P53985 1/20 0.35
CA9 Q16790 1/20 0.34
PDE4B Q07343 1/20 0.34
GRM5 P41594 1/20 0.34
MALT1 Q9UDY8 1/20 0.34
HTT P42858 1/20 0.34
NTRK1 P04629 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2917233 0.88 RPA1 (0.48) MEN1KMT2ARPA1SMN1; SMN2
SCHEMBL4470894 0.87 RPA1 (0.47) MEN1KMT2ARPA1SMN1; SMN2
SCHEMBL2917819 0.84 CA9 (0.50) MEN1KMT2ANPC1TP53RAB9A
SCHEMBL5512369 0.83 CNR1 (0.41) PTGS1PTGS2NPC1TP53RAB9A
SCHEMBL2915620 0.81 MGLL (0.53) GRM5MALT1NTRK1
SCHEMBL14529765 0.81 PDE4B (0.37) PTGS1PTGS2SMN1; SMN2SLC16A3SLC16A1
SCHEMBL14529441 0.78 KDM4E (0.44) GRM5HTTNTRK1
SCHEMBL14529445 0.78 KDM1A (0.45) PTGS1PTGS2MALT1NTRK1
SCHEMBL13637493 0.78 PTGS1 (0.41) PTGS1PTGS2NPC1TP53RAB9A
SCHEMBL14529434 0.76 MALT1 (0.49) PTGS1PTGS2MEN1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7622471-B2 Pyrazole derivatives having a pyridazine and pyridine functionality DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2009-11-24 US disclosed
US-20070219210-A1 Amidopyrazole Derivative DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2007-09-20 US disclosed
EP-1698626-A1 AMIDOPYRAZOLE DERIVATIVE DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2006-09-06 EP disclosed
US-20060128685-A1 Pyrazole derivative DAIICHI PHARMACEUTICAL CO., LTD., (JP) 2006-06-15 US disclosed
EP-1591443-A1 PYRAZOLE DERIVATIVE DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2005-11-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060128685-A1 Pyrazole derivative PTGS1, PTGS2, PTGER1 PTGS1 1/4885PTGS2 2/4885P4HTM 2882/4885
US-20070219210-A1 Amidopyrazole Derivative PTGER1, PTGS1, PTGER2 PTGS1 2/4885PTGS2 4/4885P4HTM 1499/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.